Introduction
============

In the last decade, the treatment of melanoma has been revolutionized by the introduction in the therapy of several pharmacological molecules. In particular, with the recent introduction of the immune checkpoint inhibitors and the new selective tyrosine kinase inhibitors, including BRAF and MEK inhibitors, there has been a significant improvement in the progression-free survival (PFS) and overall survival (OS) of patients with melanoma ([@B41]; [@B44]). Despite these promising results, a part of patients develops pharmacological resistance significantly reducing the effectiveness to these treatments ([@B35]; [@B21]). Several studies showed a very high mortality rate for cutaneous melanoma ranging from 2.17 to 2.7 per 100,000 persons ([@B29]; [@B43]; [@B4]). This high mortality rate is mainly linked to the aggressiveness of cutaneous melanomas ([@B28]), to the development of drug resistance ([@B24]) and to their high invasive and metastatic powers ([@B1]).

It was demonstrated that CM invasiveness is mainly due to the over-expression of several proteases, including matrix metalloproteinases (MMPs) ([@B19]; [@B34]; [@B35]). In particular, a fundamental role is played by Matrix Metalloproteinase 9 (MMP-9) that promoted melanoma invasiveness and spreading via the degradation of several components of the extracellular matrix ([@B26]; [@B42]; [@B39]; [@B17]). Of note, the MMP-9 expression is regulated by several molecular pathways ([@B14]; [@B46]) and its over-expression is associated to epigenetic events ([@B9]) and to the aberrant activation of the Ras-Raf-MEK-ERK, MAPK and PI3K/PTEN/AKT/mTOR signaling pathways ([@B7]; [@B40]). In addition, the MMP-9 expression is also regulated by several miRNAs ([@B8]; [@B47]).

Several point mutations affect key genes involved in the regulation of these pathways altering the cellular homeostasis resulting in cell proliferation, apoptosis prevention and tumor invasion ([@B48]; [@B25]). Among these point mutations, *BRAF^V600E^* represents the most frequent alteration observed in melanoma ([@B12]) and many scientific evidences suggest that *BRAF^V600E^* mutation is associated with the over-expression of MMP-9 in several tumor types, including melanoma ([@B30]; [@B13]; [@B17]). Other mutations may occur in NRAS, TERT, PTEN and, less frequently, PIK3CA ([@B48]).

The identification of these mutated genes allowed to develop new therapeutic approaches using selective inhibitors for such altered proteins. Promising results were achieved by the treatment with BRAF inhibitors alone or in combination with MEK inhibitors ([@B6]; [@B33]). However, the identification of effective biomarker of therapeutic response is still lacking ([@B27]; [@B3]; [@B32]; [@B45]).

It has been demonstrated that circulating-free DNA analysis allows to characterize the molecular features of tumors. The analysis of circulating-free DNA may be used to identify directly in serum or plasma *BRAF^V600E^* mutated clones and establish the efficacy of the treatments and the tumor aggressiveness ([@B38]; [@B18]; [@B31]). However, the reduction of circulating-free DNA *BRAF^V600E^* mutated clones, followed by the treatment with BRAF inhibitors, was not directly associated with clinical efficacy ([@B2]; [@B38]). Therefore, there is a need to identify new markers that can be associated with the MAPK pathway modulation as consequence of BRAF inhibitors treatment. Among these, MMP-9 may be a right marker candidate easily detected in the peripheral blood samples from melanoma patients. Moreover, MMP-9 was demonstrated to be a marker of aggressiveness in several tumors, including melanoma ([@B9]; [@B48]); while, its role as an indicator of therapeutic response was not fully investigated yet.

On these bases, in the present study functional experiments were performed using melanoma cell models to confirm the correlation between MMP-9 expression and MAPK pathway modulation during the treatment with BRAF inhibitors. Validation of *in vitro* data were assessed in peripheral blood samples from melanoma patients analyzing MMP-9 levels according to the presence of circulating-free DNA *BRAF^V600E^* mutation.

Materials and Methods {#s1}
=====================

Cell Lines and Treatment
------------------------

The A375 and A2058 melanoma cell lines were purchased from ATCC (Rockville, MD, United States). Both cell lines were cultured in RPMI-1640 medium supplemented with [L]{.smallcaps}-glutamine (2 mmol/L), penicillin (100 IU), streptomycin (100 μg/ml) and 10% fetal bovine serum (FBS) (all provided from GIBCO TM) and grown in humidified incubator (5% CO~2~) at 37°C. The cell lines were seeded in 60 mm cell-culture dishes (Thermo Fisher Scientific Inc., Waltham, MA, United States) at a density of 300,000 cells/well and 400,000 cells/well for A375 and A2058, respectively.

A375 cells were treated with dabrafenib (dissolved in DMSO) (cat. n. S2807 - Selleckchem, United States) at the concentration of 2, 1, 0.5, 0.25, 0.125 nM, whereas A2058 cells were treated with 32, 16, 8, 4, 2 nM of dabrafenib. DMSO was used as control. Both cell lines were treated for 12, 24, and 48 h.

Dabrafenib resistant A375 cells were obtained by culturing the cells with growing concentration of dabrafenib (up to 70 nM) for 2 months. Parental A375 and resistant A375 cells both untreated and treated with 70 nM dabrafenib were seeded in triplicate in 60 mm cell-culture dishes for 48 h.

For each cellular condition, conditioned supernatants were collected and cleaned up from debris by centrifugation. Adherent cells were collected by scraper after washing once in cold 1X DPBS GIBCO TM (cat. n. 14190250 - Thermo Fisher Scientific Inc., Waltham, MA, United States). Cell pellets were collected by centrifugation and stored at -80°C. All experiments were conducted in triplicate.

ELISA
-----

ELISA test was performed to detect MMP-9 levels in A375 and A2058 culture supernatants using MMP-9 Human ELISA Kit (cat. n. BMS2016-2 - Invitrogen Corporation, Carlsbad, CA, United States) according to the manufacturer's instructions. Whereas, Human MMP-9 Quantikine ELISA KIT (cat. n. DMP900 - R&D Systems, Minneapolis, MN, United States) was used to detect serum levels of MMP-9 in melanoma patients enrolled in this study. Optical density (OD) was measured by Tecan ELISA plate reader (Tecan, Männedorf, Switzerland). Linear regression analysis was performed to generate standard curve from average absorbance of standards. MMP-9 concentrations were calculated fitting the average of duplicate ODs of each sample with standard curve.

Real-Time PCR Quantification of MMP-9 Transcript Levels
-------------------------------------------------------

Total RNA was extracted from cellular pellet by using the PureLink RNA mini RNA extraction kit (cat. n. 12183025 - Ambion/Life Technologies, Carlsbad, CA, United States) according to the manufacturer's instructions. For each sample, 1 μg of total RNA was reverse transcribed using SuperScript III Reverse Transcriptase kit (cat. n. 18080044 - Thermo Fisher Scientific Inc., Waltham, MA, United States). First-strand cDNA was used for quantitative PCR (qPCR) reactions performed using the AB 7300 Real-Time PCR system (Applied Biosystems, Foster City, CA, United States). Amplification was performed using Fast SYBR Green Master Mix (cat. n. 4385617 -- Applied Biosystems, Foster City, CA, United States) according to the conditions reported below:

Initial denaturation at 95°C for 10 min, followed by 40 cycles at 95°C for 15 s and 60°C for 1 min. Relative expression of MMP-9 transcript was performed using the 2^-ΔΔCt^ method. For the detection of MMP-9 transcript the following primers were used:

Forward 5′-GAACCAATCTCACCGACAGG-3′; Reverse 5′-CCACAACTCGTCATCGTCG-3′. The phosphoglycerate kinase 1 (PGK1) housekeeping gene was used as an internal control for result normalization.

PGK1 primer sequences were: Forward 5′-TTAAAGGGAAGCGGGTCGTT-3′; Reverse 5′-CAGGCATGGGCACACCAT-3′.

Western Blot
------------

Cellular pellets were lysed in NP-40 cell lysis buffer (cat. n. FNN0021 - Thermo Fisher Scientific Inc., Waltham, MA, United States) supplemented with protease and phosphatase inhibitor cocktails (Sigma, St. Louis, MO, United States). Quick Start^TM^ Bradford 1X Dye Reagent assay (cat. n. 5000205 - Bio-Rad Laboratories, Inc., Hercules, CA, United States) was used to quantify protein amount. For each sample, 30 μg of proteins were electrophoretically separated using 4--15% Mini Protean TGX Precast Gels (cat. n. 4561083 - Bio-Rad Laboratories, Inc., Hercules, CA, United States). Bio-Rad Trans-Blot Turbo was used to transfer the gel proteins into a PVDF/nitrocellulose membrane (Bio-Rad Laboratories, Inc.). Primary antibody Anti-MAP Kinase ERK1/ERK2 (pThr202/pThr204) rabbit Ab (diluted 1:1000 - cat. n. 442685) and Anti-MAP Kinase ERK1/ERK2 rabbit Ab (diluted 1:1000 - cat. n. 442704) (Merck Millipore, Darmstadt, Germany) were used to detect phosphorylated and total ERK 1/2 proteins.

Tubulin housekeeping protein was detected by using Anti-beta Tubulin rabbit Ab (diluted 1:1000 -- cat. n. 15568- Abcam, Cambridge, United Kingdom). Chemiluminescent detection was performed using Clarity Western ECL Substrate (cat. n. 1705060 - Bio-Rad Laboratories, Inc., Hercules, CA, United States). Western blot images were collected by Bio-Rad ChemiDoc Touch Imaging System and analyzed with ImageJ software (National Institutes of Health, Bethesda, MD, United States). All Western blot experiments were performed in triplicate.

Melanoma Patients
-----------------

In this study 28 melanoma patients treated with BRAF inhibitors (53.5%) alone or in combination with MEK inhibitors (46.5%) were included. Informed consent forms were signed by each participant, and appropriate ethical committee approval was obtained. For each patient socio-demographics, clinical-pathological and therapeutics data were reported in **Table [1](#T1){ref-type="table"}**. Peripheral blood samples were collected from patients prior each cycle of chemotherapy. Serum and plasma were obtained by centrifugation at 2,000 *g* for 10 min and immediately frozen (-80°C) until further analysis. All patients were enrolled at National Cancer Institute "Fondazione Giovanni Pascale," Naples (Italy) and accepted the informed consent, according to the recommendations of the Board of Ethics of the study hospitals.

###### 

Distribution of 28 patients with melanoma according to socio-demographic and clinical characteristics.

                                            All   Cancer progression   Vital status                                                     
  ----------------------------------------- ----- -------------------- -------------- ------------- ----- -------- ----- -------- ----- --------
                                            *n*   (%)                  *n*            (%)           *n*   (%)      *n*   (%)      *n*   (%)
  **Sex**                                                                                                                               
  Man                                       14    (50.0)               2              (40.0)        12    (52.2)   4     (44.4)   10    (52.6)
  Woman                                     14    (50.0)               3              (60.0)        11    (47.8)   5     (55.6)   9     (47.4)
  Fisher test                                                          *p* = 1.000    *p* = 1.000                                       
  **Age at treatment initiation (years)**                                                                                               
  \<45                                      11    (39.3)               2              (40.0)        9     (39.1)   5     (55.6)   6     (31.6)
  45--59                                    10    (35.7)               1              (20.0)        9     (39.1)   1     (11.1)   9     (47.4)
  ≥60                                       7     (25.0)               2              (40.0)        5     (21.7)   3     (33.3)   4     (21.1)
  Fisher test                                                          *p* = 0.824    *p* = 0.195                                       
  **Melanoma type**                                                                                                                     
  S.P.I.                                    6     (21.4)               1              (20.0)        5     (21.7)   2     (22.2)   4     (21.1)
  Cutaneous                                 22    (78.6)               4              (80.0)        18    (78.3)   7     (77.8)   15    (79.0)
  Fisher test                                                          *p* = 1.000    *p* = 1.000                                       
  **Stage**                                                                                                                             
  M1a                                       7     (25.9)               2              (20.0)        5     (22.7)   2     (22.2)   5     (27.8)
  M1b                                       4     (14.8)               1              (10.0)        3     (13.6)   2     (22.2)   2     (11.1)
  M1c                                       16    (59.3)               2              (20.0)        14    (63.6)   5     (55.6)   11    (61.1)
  Fisher test                                                          *p* = 0.502    *p* = 0.726                                       
  **Therapy**                                                                                                                           
  Monotherapy                               15    (57.7)               1              (20.0)        14    (60.9)   4     (44.4)   11    (57.9)
  Combo                                     13    (42.3)               4              (80.0)        9     (39.1)   5     (55.6)   8     (42.1)
  Fisher test                                                          *p* = 0.153    *p* = 0.689                                       
  **LDH**                                                                                                                               
  \<480                                     17    (80.0)               4              (80.0)        13    (56.5)   6     (66.7)   11    (57.9)
  ≥480                                      11    (20.0)               1              (20.0)        10    (43.5)   3     (33.3)   8     (42.1)
  Fisher test                                                          *p* = 0.620    *p* = 1.000                                       

Circulating-Free DNA Isolation
------------------------------

Circulating-free DNA isolation was obtained from serum of melanoma samples enrolled in the present study according to manual protocols adapted from Hufnagl C and colleagues ([@B20]). Briefly, 1 mL of serum, 100 μL of solution composed by EDTA (250 mmol/L) and NaCl (750 mmol/L), 100 μL of 100 g/L sodium dodecyl sulfate and 40 μL of proteinase K (stock solution 20 mg/mL) were added. After 2 h incubation at 56°C, the proteins were precipitated with 200 μL of saturated 6M NaCl solution (final concentration of 0.86 mol/L). The circulating-free DNA was extracted from supernatant by phenol-chloroform mixture at room-temperature (RT). After 5 min of incubation at RT, mixture was centrifuged for 15 min at 14,000 *g*. The upper phase was transferred in a new tube and mixed to an equal volume of absolute ethanol and then incubated over night at -20°C. The DNA was centrifuged for 15 min at 14,000 *g*. The precipitated pellet was first washed with 70% ethanol and finally dissolved in 20 μL of DNAse and RNAse free water. For two of 28 samples the extracted circulating-free DNA was found to be excessively degraded and therefore the circulating-free DNA *BRAF^V600E^* mutation detection was not performed.

Circulating-Free DNA BRAF^V600E^ Mutation Detection
---------------------------------------------------

The *BRAF^V600E^* mutation was detected in circulating-free DNA using Bio-Rad droplet PCR analysis system (Bio-Rad Laboratories, Inc., Hercules, CA, United States), according to the manufacturer's protocol. Briefly, a 22 μl of reaction mixture was prepared by mixing 11 μL ddPCR Supermix for probes (no dUTP -- cat. n. 1863010), 1 μl of Bio-Rad BRAF-V600E FAM/HEX mixture (cat. n. dHsaMDV2010027), 5 μl of circulating-free DNA sample and 5 μl of PCR water. Twenty microliters of PCR reaction was loaded on the cartridge contending 70 μl of Droplet Generation Oil (cat. n. 1863005 - Bio-Rad Laboratories, Inc., Hercules, CA, United States) in appropriate wells, and then Droplet Generator QX100 was used to generate the nano-sized droplets. Droplet mixture was transferred in PCR plate and amplified by C 1000 Touch Thermal Cycler (Bio-Rad Laboratories, Inc., Hercules, CA, United States) under the following cycling conditions: 10 min at 95°C, 40 cycles of 94°C for 30 s, 55°C for 1 min, followed by 98°C for 10 min (ramp rate 2°C/s).

Fluorescent signals were detected using QX200 Droplet Reader (Bio-Rad Laboratories, Inc., Hercules, CA, United States) and analyzed using QuantaSoft software, version 1.7.4 (QuantaSoft, Prague, Czechia). Samples were considered positive when three or more FAM/HEX-positive droplets were detected. Absolute quantification (copies/mL) were determined using the QuantaSoft software.

Statistical Analysis
--------------------

MMP-9 mRNA expression, MMP-9 supernatant level and pERK/ERK ratio in treated melanoma cells and relative control were compared using two-tailed Student's *t*-test. Fisher exact test was used to determine the association between clinical characteristics and cancer progression and vital status. Mann-Whitney test was used to compare the serum concentration of MMP-9 clustered melanoma patients according to clinical-pathological parameters.

Progression-free survival was calculated from the date of treatment initiation to progression, death, or end of follow-up, whichever occurred first. OS was calculated from the date of treatment initiation to patients' death. Survival curves were estimated through Kaplan--Meier method; log-rank non-parametric test was used to compare the survival distributions of melanoma patients according to the detectability of circulating-free DNA *BRAF^V600E^* mutation and the MMP-9 serum concentration. Statistically significant difference was considered when *p* ≤ 0.05 (two-tailed).

Results
=======

MMP-9 Expression Levels in Melanoma Cells Sensitive and Resistant to Dabrafenib
-------------------------------------------------------------------------------

To test the hypothesis that MMP-9 expression is associated with MAPK pathway modulation, induced by the treatment with BRAF inhibitors, A375 and A2058 melanoma cells harboring *BRAF^V600E^* mutation were used.

ELISA and Real-Time PCR analyses showed that MMP-9 was statistically down-regulated (*p* \< 0.05) in A375 and A2058 melanoma cell lines after treatment with dabrafenib for 48 h (**Figures [1A,B](#F1){ref-type="fig"}, [2A,B](#F2){ref-type="fig"}**). No significant MMP-9 modulation was observed when the cell lines were treated for 12 and 24 h (data not shown). Similar trend was observed for pERK1-2 protein levels detected by Western Blot in both A375 and A2058 cell lines at 12, 24, and 48 h (*p* \< 0.05) (**Figures [1C,D](#F1){ref-type="fig"}, [2C,D](#F2){ref-type="fig"}**).

![Dabrafenib treatment of A375 cell line. MMP-9 expressionlevels were evaluated by qPCR **(A)** and ELISA Assay **(B)** in A375 cell line treated with increasing doses of dabrafenib (0.125, 0.25, 0.5, 1, and 2 nM) for 48 h. pERK and total ERK protein levels were evaluated by Western blot analysis after treatment with dabrafenib for 12, 24, and 48 h **(C,D)**. The statistical significance of the two-tailed Student's *t*-test was referred to the control. ^∗^*p* \< 0.05; ^∗∗^*p* \< 0.01.](fphar-09-00856-g001){#F1}

![Dabrafenib treatment of A2058 cell line. A2058 cell line was treated with different doses of dabrafenib (2, 4, 8, 16, and 32 nM) for 12, 24, and 48 h. Real-Time PCR **(A)** and ELISA assay **(B)** were performed to evaluate MMP-9 expression levels of A2058 after 48 h of treatment. pERK and total ERK protein levels in A2058 cells treated with dabrafenib at 12, 24, 48 h were evaluated by Western blot **(C,D)**. The statistical significance of the two-tailed Student's *t*-test was referred to the control. ^∗^*p* \< 0.05; ^∗∗^*p* \< 0.01.](fphar-09-00856-g002){#F2}

To verify if MMP-9 may be involved in the mechanism of resistance to BRAF inhibitors, such as dabrafenib, resistant clones of A375 were used. Both higher mRNA and protein MMP-9 expression levels were observed in the A375 resistant clones compared to those detected in the parental cells. As expected, the increase of MMP-9 expression was independent to the treatment with dabrafenib (**Figures [3A,B](#F3){ref-type="fig"}**). To further investigate the effects of resistance to dabrafenib on MAPK pathway, pERK1-2 levels in resistant clones were measured. pERK1-2 levels were higher in resistant clones when compared with sensitive parental cells (*p* \< 0.05) (**Figures [3C,D](#F3){ref-type="fig"}**).

![MMP-9 expression in A375 cell resistant to dabrafenib. MMP-9 expression levels were evaluated in, A375 parental clone, A375 dabrafenib resistant clones with and without addition of 70 nM of dabrafenib to RMPI-1640 medium **(A,B)**. Western Blot analysis was performed to evaluate pERK levels in resistant clones e control cell line after 48 h **(C,D)**. The statistical significance of the two-tailed Student's *t*-test was referred to the control. ^∗^*p* \< 0.05; ^∗∗^*p* \< 0.01.](fphar-09-00856-g003){#F3}

These *in vitro* data showed that BRAF inhibitor efficiently counteracts the MAPK signal pathway in A375 cells where the concomitant decrease of pERK and MMP-9 levels was observed in a dose-dependent manner. In contrast, activation of pERK was observed in resistant cell clones with concomitant MMP-9 overexpression. These encouraging data support the notion that MMP-9 may be considered a marker of response to dabrafenib in melanoma cells.

Circulating MMP-9 Expression Levels in Peripheral Blood From Melanoma Patients Treated With BRAF Inhibitors
-----------------------------------------------------------------------------------------------------------

MMP-9 serum levels were evaluate in melanoma samples according to socio-demographic, clinical and molecular features, including the presence of circulating-free DNA *BRAF^V600E^* mutation (**Table [2](#T2){ref-type="table"}**). Such mutation was identified in 11 out of 26 melanoma patients (42%). Notably, MMP-9 higher levels were observed in patients with detectable circulating-free DNA *BRAF^V600E^* mutation compared to those with undetectable *BRAF^V600E^* mutation (*p* = 0.058). In agreement with these data, it appears speculating that higher levels of MMP-9 are associated with the spreading of tumor DNA in the bloodstream where *BRAF^V600E^* mutation is detectable (**Table [2](#T2){ref-type="table"}**). Accordingly, the PFS and OS are higher in melanoma patients with undetectable circulating-free DNA *BRAF^V600E^* mutation compared with those harboring the detectable mutation (*p* = 0.004 and *p* = 0.007 respectively) (**Table [3](#T3){ref-type="table"}** and **Figures [4A,C](#F4){ref-type="fig"}**). These data indicate that the detectability of circulating-free DNA *BRAF^V600E^* mutation may be considered as a negative prognostic factor. Although no statistics significance has been reached due to the low number of patients, it was observed that highest MMP-9 levels were associated with a lower PFS and OS (**Table [3](#T3){ref-type="table"}** and **Figures [4B,D](#F4){ref-type="fig"}**). No statistical difference was observed for both PFS and OS in patients treated with monotherapy or combination therapy (**Table [3](#T3){ref-type="table"}**).

###### 

MMP-9 concentration at baseline in serum of 28 patients with melanoma according to socio-demographic, clinical characteristics and molecular features.

                                            *n*   MMP-9 (ng/mL)   Mann--Whitney test   
  ----------------------------------------- ----- --------------- -------------------- -------------
  Overall                                         684             427--1118            
  **Sex**                                                                              
  Man                                       14    684             417--1108            *p* = 0.927
  Woman                                     14    662             437--1128            
  **Age at treatment initiation (years)**                                              
  \<45                                      11    601             482--1148            *p* = 0.807
  45--59                                    10    870             352--882             
  ≥60                                       7     670             354--1108            
  **Melanoma type**                                                                    
  S.P.I.                                    6     1204            417--1930            *p* = 0.131
  Cutaneous                                 22    636             437--873             
  **Stage**                                                                            
  M1a                                       7     601             482--723             *p* = 0.624
  M1b                                       4     614             470--1801            
  M1c                                       16    872             427--1159            
  **Therapy**                                                                          
  Monotherapy                               15    697             437--1108            *p* = 0.596
  Combo                                     13    670             352--1128            
  **LDH**                                                                              
  \<480                                     17    671             482--882             *p* = 0.796
  ≥480                                      11    686             354--1238            
  ****BRAF*^*V600E*^***                                                                
  Undetectable                              15    557             354--722             *p* = 0.058
  Detectable                                11    873             437--1238            

###### 

Median time to progression (TTP) and progression free survival (PFS) in 28 patients with melanoma according to BRAF and MMP-9.

                                                                        Patients   Progressions   Median TTP (days)   PFS                          Deaths   OS                                                 
  --------------------------------------------------------------------- ---------- -------------- ------------------- ---------------------------- -------- ---------------------------- ---- ------- -------- --------
                                                                                                                      6 mos                        12 mos   24 mos                            6 mos   12 mos   24 mos
  Overall                                                               28         23             219                 67.9%                        39.3%    17.9%                        14   92.9%   71.4%    46.4%
  ***BRAF**^**V600E**^*                                                                                                                                                                                        
  Undetectable                                                          15         10             280                 80.0%                        60.0%    33.3%                        5    93.3%   93.3%    66.7%
  Detectable                                                            11         11             219                 54.6%                        9.1%     0.0%                         9    90.9%   45.5%    18.2%
                                                                                                  *p* = 0.398         Log-rank test: *p* = 0.004            Log-rank test: *p* = 0.007                         
  **MMP-9 at treatment initiation (ng/mL)**                                                                                                                                                                    
  \<680                                                                 14         11             240                 78.6%                        42.9%    21.4%                        6    100%    85.7%    57.1%
  ≥680                                                                  14         12             195                 57.1%                        35.7%    14.3%                        9    85.7%   57.1%    35.7%
                                                                                                  *p* = 0.450         Log-rank test: *p* = 0.415            Log-rank test: *p* = 0.219                         
  ***BRAF**^**V600E**^* **and MMP-9 at treatment initiation (ng/mL)**                                                                                                                                          
  Undetectable and \<680                                                10         7              353                 90.0%                        60.0%    30.0%                        3    100%    100%     70.0%
  Undetectable and ≥680                                                 5          3              153                 60.0%                        60.0%    40.0%                        2    80.0%   80.0%    60.0%
  Detectable and \<680                                                  4          4              205                 50.0%                        0.0%     0.0%                         3    100%    50.0%    25.0%
  Detectable and ≥680                                                   7          7              219                 57.1%                        14.3%    0.0%                         6    85.7%   42.9%    14.3%
                                                                                                  *p* = 0.153         Log-rank test: *p* = 0.037            Log-rank test: *p* = 0.056                         
  **Therapy**                                                                                                                                                                                                  
  Monotherapy                                                           15         14             206                 60.0%                        26.7%    0.0%                         9    100%    60.0%    40.0%
  Combo                                                                 13         9              240                 76.9%                        53.9%    30.8%                        6    84.6%   84.6%    53.9%
                                                                                                  *p* = 0.705         Log-rank test: *p* = 0.102            Log-rank test: *p* = 0.496                         

![Melanoma patients PFS and OS. Kaplan--Meier estimate of PFS and OS in patients with detectable (dotted line) and undetectable (continuous line) *BRAF^V600E^* (PFS log-tank test: *p* = 0.004; OS log-tank test: *p* = 0.007) **(A,C)**. PFS and OS evaluations in patients with MMP-9 serum concentration at baseline (continuous line: \< 680 ng/mL; dotted line: ≥ 680 ng/mL; PFS log-tank test: *p* = 0.415; OS log-tank test: *p* = 0.219) **(B,D)**.](fphar-09-00856-g004){#F4}

In addition, the percentage of MMP-9 serum variations at different times during the treatment with BRAF inhibitors were analyzed in melanoma patients. Such variations were also evaluated according to the detectability of circulating-free DNA *BRAF^V600E^* mutation. No significant percentage variations of MMP-9 serum levels were observed in melanoma patients at different times during the treatment with BRAF inhibitors (data not shown). While, a significant percentage of MMP-9 decrement in samples with circulating-free DNA *BRAF^V600E^* mutation compared to those with undetectable one was observed at T1 and T2 (**Figure [5](#F5){ref-type="fig"}**). Such percentage of MMP-9 decrement was not observed at T-last where novel microenvironmental factors and/or genetic alteration may occur conferring a drug resistance phenotype to the tumor cells (**Figure [5](#F5){ref-type="fig"}**). These data indicate that the MMP-9 decrement is more evident during the first week of treatment, where the therapy is effective, in melanoma patients with detectable circulating-free DNA *BRAF^V600E^* mutation. However, at last follow-up MMP-9 decrement in those patients is not significant compared to patients with undetectable *BRAF^V600E^* mutation, suggesting that the treatment became ineffective.

![MMP-9 reduction in patients with *BRAF^V600E^* mutation at different time. Percentage variation of MMP-9 from baseline to first (T1) and second (T2) clinical examination after treatment initiation and to last follow-up (T-last) according to circulating *BRAF^V600E^* mutation.](fphar-09-00856-g005){#F5}

Discussion
==========

In the last decade, the treatment with BRAF and MEK kinase inhibitors improved the prognosis of advanced melanoma. However, a significant fraction of these patients experiences progression disease. The identification of new biomolecular markers of progression disease and acquired resistance may lead to change therapeutic setting and, eventually, reduce overtreatment ([@B11], [@B10]; [@B23]).

Improvement of liquid biopsy through the recent advances in molecular technologies, such as the development of digital polymerase chain reaction (dPCR), led to identify tumor molecular features by analyzing the circulating-free DNA harboring pathogenetic mutations ([@B5]; [@B15]). Several studies showed that detection of circulating-free DNA *BRAF^V600E^* mutations is predictive of the response to MAPKs inhibitors in melanoma treatment. In particular, high basal levels of circulating-free DNA *BRAF^V600E^* mutation are associated with poor response to therapy and PFS and OS ([@B2]; [@B36]; [@B37]; [@B22]). Furthermore, it has been demonstrated that increase of circulating-free DNA BRAF mutation during treatment is predictive of acquired resistance and therapeutic failure ([@B16]).

To the best of our knowledge, no previous studies have identified new markers that can be linked with the MAPK pathway modulation after treatment with BRAF inhibitors. However, MMP-9 has been associated with the aberrant activation of MAPK pathway in melanoma, suggesting its role as prognostic indicator ([@B17]). Therefore, in the present study, the modulation of MMP-9 in melanoma after treatment with B-RAF inhibitors was analyzed through different experimental approaches.

Our *in vitro* data showed that BRAF inhibitor efficiently counteracts the MAPK signal pathway in A375 cells where the concomitant decrease of pERK and MMP-9 levels was observed in a dose-dependent manner. Furthermore, to verify if MMP-9 may be involved in the mechanism of resistance to BRAF inhibitors A375 resistant cells were obtained and pERK protein levels showed opposite behavior compared to sensitive cells when treated with dabrafenib. In particular, an activation of pERK was observed in resistant cell clones with concomitant MMP-9 overexpression. These encouraging data support the notion that MMP-9 may be considered a marker of response to dabrafenib in melanoma cells.

After the *in vitro* evaluations, circulating-free DNA *BRAF^V600E^* mutation and MMP-9 serum levels were evaluated in melanoma patients. Unexpectedly, circulating-free DNA *BRAF^V600E^* mutation was detected in only the 42% (11 out of 26) of melanoma patients positive to *BRAF^V600E^* mutation after the histopathological diagnosis. Interestingly, ELISA assay showed that MMP-9 serum levels where higher in patients with detectable circulating-free DNA *BRAF^V600E^* mutation compared to those with undetectable *BRAF^V600E^* mutation suggesting that the increase of MMP-9 in the subset of patients with detectable circulating mutation are associated with the spreading of tumor and in the release of circulating-free DNA in the bloodstream. These evidences encourage the use of MMP-9 as a prognostic marker in the subsets of patients with detectable circulating mutation, where the concomitant evaluation of circulating-free DNA status and MMP-9 serum levels may give important information about the prognosis of patients.

Indeed, the PFS and OS analyses according to the circulating-free DNA *BRAF^V600E^* status and the MMP-9 expression levels showed a worse prognosis for melanoma patients with detectable circulating *BRAF^V600E^* mutation and high MMP-9 serum levels (\>680 ng/mL) compared with those with undetectable mutation and lower levels of MMP-9.

Finally, the analysis of MMP-9 during the treatment showed that MMP-9 serum protein levels significantly decreased at T1 and T2, but not at the last follow-up, for the patients with detectable circulating-free DNA *BRAF^V600E^* mutation.

Overall, the results of the present study confirm that the occurrence of circulating-free DNA *BRAF^V600E^* mutation is a negative prognostic factor of cutaneous melanoma; furthermore, MMP-9 may be considered a prognostic indicator of response to BRAF inhibitors only in the subset of patients harboring the circulating-free DNA *BRAF^V600E^* mutation supporting the notion that MMP-9 is associated with the MAPK pathway. Further studies, including a larger series of melanoma patients, are needed to better clarify the impact of MMP-9 as a marker of response to treatment with BRAF inhibitors.
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